198 related articles for article (PubMed ID: 24925052)
1. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
Queisser A; Hagedorn SA; Braun M; Vogel W; Duensing S; Perner S
Mod Pathol; 2015 Jan; 28(1):138-45. PubMed ID: 24925052
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
3. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
4. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer.
Ferrari AC; Stone NN; Eyler JN; Gao M; Mandeli J; Unger P; Gallagher RE; Stock R
J Natl Cancer Inst; 1997 Oct; 89(20):1498-504. PubMed ID: 9337346
[TBL] [Abstract][Full Text] [Related]
5. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.
Varinot J; Furudoï A; Drouin S; Phe V; Penna RR; Roupret M; Bitker MO; Cussenot O; Compérat E
Virchows Arch; 2016 May; 468(5):619-22. PubMed ID: 26931741
[TBL] [Abstract][Full Text] [Related]
6. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
[TBL] [Abstract][Full Text] [Related]
7. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor status of lymph node metastases from prostate cancer.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
11. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Sweat SD; Pacelli A; Murphy GP; Bostwick DG
Urology; 1998 Oct; 52(4):637-40. PubMed ID: 9763084
[TBL] [Abstract][Full Text] [Related]
13. Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Cancer Res; 1995 Jul; 55(14):3068-72. PubMed ID: 7541709
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
15. [Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature].
Junca A; Frouin E; Irani J; Fromont G; Levillain P
Ann Pathol; 2015 Dec; 35(6):496-501. PubMed ID: 26597142
[TBL] [Abstract][Full Text] [Related]
16. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
Schmidkonz C; Cordes M; Beck M; Goetz TI; Schmidt D; Prante O; Bäuerle T; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
[TBL] [Abstract][Full Text] [Related]
17. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific membrane antigen expression in melanoma metastases.
Snow H; Hazell S; Francis N; Mohammed K; O'Neill S; Davies E; Mansfield D; Messiou C; Hujairi N; Nicol D; Harrington K; Smith M
J Cutan Pathol; 2020 Dec; 47(12):1115-1122. PubMed ID: 32529651
[TBL] [Abstract][Full Text] [Related]
19. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B).
Yamamichi F; Matsuoka T; Shigemura K; Kawabata M; Shirakawa T; Fujisawa M
Urology; 2012 Oct; 80(4):951.e1-7. PubMed ID: 22920407
[TBL] [Abstract][Full Text] [Related]
20. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
[Next] [New Search]